Navigation Links
Harwood Feffer LLP Announces Investigation of Questcor Pharmaceuticals, Inc.
Date:9/20/2012

NEW YORK, Sept. 20, 2012 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of Questcor Pharmaceuticals, Inc. ("Questcor" or the "Company") (NASDAQ: QCOR), concerning whether the board has breached its fiduciary duties to shareholders.

(Logo:  http://photos.prnewswire.com/prnh/20120215/MM54604LOGO)

Questcor derives substantially all of its revenue from the sale of Repository Corticotropin Injection, also known as HP Acthar Gel (Acthar).  On September 14, 2012, one of the largest private insurance providers in the United States, Aetna, issued a Clinical Policy Bulletin stating that based on review of medical studies, Acthar was "not medically necessary" for several conditions for which it has been prescribed, as a result, Aetna would cease coverage of Acthar for those conditions.  The directors of Questcor owes fiduciary obligation to the Company and its shareholders in the management of the Company's assets.

Questcor shares have fallen over 48% since September 7, 2012, when Company stock closed as high as $51.97 per share.  Questcor is currently trading at $27.33 per share.

Current holders of Questcor shares purchased at any time may have a claim against the board for breaches of fiduciary duties, gross mismanagement, and/or abuse of control.  If you own Questcor shares and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:

Robert I. Harwood, Esq.
Matthew M. Houston, Esq.
Christopher J. Safrath
Harwood Feffer LLP
488 Madison Avenue
New York, New York 10022
Phone Numbers: (877) 935-7400
(212)935-7400
Email:        csafrath@hfesq.com
Website:    http://www.hfesq.com

Harwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the Harwood Feffer LLP website (http://www.hfesq.com) for more information about the firm.

Attorney Advertising. © 2012 Harwood Feffer LLP. The law firm responsible for this advertisement is Harwood Feffer LLP (www.hfesq.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter.


'/>"/>
SOURCE Harwood Feffer LLP
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cyberonics Announces Investment In cerbomed GmbH
2. ULURU Inc. Announces First Order Of Altrazeal For European Launch
3. United Therapeutics Announces Collaboration With Ascendis Pharma To Develop Self-Injectable Treprostinil For Pulmonary Arterial Hypertension
4. FDAnews announces Third Annual Pharmaceutical Labeling Summit
5. CVS Caremark Corporation Announces New Share Repurchase Authorization for up to $6 Billion of Common Stock
6. PRN Physician Recommended Nutriceuticals announces partnership with Dr. Eric Donnenfeld and expansion in the New York City metropolitan area
7. InnoPharma, Inc., Announces U.S. FDA Approval of Acetylcysteine Solution, USP, 20% for Inhalation or Oral Administration
8. Specialty Pharmacy Certification Board Announces Inaugural Board of Directors
9. Valeant Pharmaceuticals Announces Launch of Concurrent Private Offerings of Senior Notes
10. Golden Meditech Holdings Limited Announces Updates on Medical Devices Subsidiary Latest Development
11. Active Life Announces Launch of Next Generation BioDentTM for Life Science Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... -- Research and Markets has announced the addition ... Types, OTC Amplifiers, Diagnostic Instruments), Sales Volume, Company Analysis and ... ... Market Sales Volume, Company Analysis and Forecast to 2022 provides ... The growing prevalence of hearing impairment coupled with ...
(Date:1/20/2017)... BUFFALO, N.Y. , Jan. 20, 2017 /PRNewswire/ ... health programs, has announced the launch of an ... to new guidelines on opioids and helps stem ... Opioids are often prescribed to treat chronic non-cancer ... disease) despite serious risks and lack of evidence ...
(Date:1/19/2017)... , Jan. 19, 2017 ... Summary GlobalData,s new report, "Germany Cataract Surgery Devices ... the Germany Cataract Surgery Devices market. The report provides ... and average prices (USD) within market segements - Phacoemulsification ... also provides company shares and distribution shares data for ...
Breaking Medicine Technology:
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... 5,000 SF expansion and facility enhancement of their 503A compounding pharmacy located in ... the growing demand of physicians and patients throughout the United States for high-quality ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... for tech innovators, engineers, and scientists from around the world, announces the launch ... users a quick and easy portal to research breakthroughs and trending news, vital ...
(Date:1/19/2017)... ... January 19, 2017 , ... Cosmetic Town, an online plastic surgery ... order to make it easier for their readers to get the information they desire. ... as well as the techniques used on those particular areas. , “We are excited ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... dermatologist by the American Board of Dermatology and fellowship trained Mohs and cosmetic ... National Institutes of Health, Dr. Li completed his internship in internal medicine at ...
(Date:1/19/2017)... , ... January 19, 2017 , ... ... a doctor who administered fillers that resulted in severe facial disfiguration. After four ... taken on by doctors at UCLA Medical Center, who removed the substances in ...
Breaking Medicine News(10 mins):